CTOs on the Move

MSI

www.methylationsciences.com

 
MSI Methylation Sciences Inc. (“MSI”) is a clinical-stage pharmaceutical company focused on developing new products based on molecules which have clinical proof of concept but which have yet to be exploited in the major pharmaceutical markets. MSI`s focus is in the CNS space where clinical proof of concept is key to reducing the drug development risk. Our lead product candidate, Strada™, is based upon Ademetionine, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle. Our disease indication is Major Depressive Disorder (MDD).
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

MSI raised $30M on 10/07/2016

Similar Companies

Westborough Behavioral Healthcare Hospital

Westborough Behavioral Healthcare Hospital is a mental health care hospital that provides consistent levels of excellent service and an attitude of caring expressed by the entire organization.

New Century Health

New Century Health delivers specialty care management solutions that leverage technology and evidence-based medicine at the point-of-care, with a focus on oncology and cardiology. Our services promote the most effective treatment, reduce variability, improve clinical outcomes, and optimize cost-effectiveness.

Revealix

Were leading a fundamental rethinking of how diabetic limb complications are detected and monitored: noninvasive, mobile & point-of-care. Techstars backed!

Healthcare Network Inc

Healthcare Network Inc is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fruit Street

Fruit Street delivers the CDC`s Diabetes Prevention Program using telehealth, wearable devices, and mobile applications. The diabetes prevention program is a 1-year long diet and lifestyle intervention designed to help pre-diabetic patients lose 5-7% of their weight through diet and lifestyle changes. The program is based on clinical research that was published in the New England Journal of Medicine in 2002 which showed that patients who complete the program have a 58% risk reduction for developing diabetes.